Connection

DAOYAN WEI to Humans

This is a "connection" page, showing publications DAOYAN WEI has written about Humans.
Connection Strength

0.268
  1. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2024 02 16; 30(4):655-662.
    View in: PubMed
    Score: 0.018
  2. Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma. Mol Cancer Ther. 2023 06 01; 22(6):693-705.
    View in: PubMed
    Score: 0.017
  3. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. Dig Dis Sci. 2023 07; 68(7):3043-3058.
    View in: PubMed
    Score: 0.017
  4. Pancreatic Acinar-to-Ductal Metaplasia and Pancreatic Cancer. Methods Mol Biol. 2019; 1882:299-308.
    View in: PubMed
    Score: 0.013
  5. Novel and emerging innate immune therapeutic targets for pancreatic cancer. Expert Opin Ther Targets. 2018 12; 22(12):977-981.
    View in: PubMed
    Score: 0.013
  6. Context-dependent functions of KLF4 in cancers: Could alternative splicing isoforms be the key? Cancer Lett. 2018 12 01; 438:10-16.
    View in: PubMed
    Score: 0.012
  7. The Role of CD44 and Cancer Stem Cells. Methods Mol Biol. 2018; 1692:31-42.
    View in: PubMed
    Score: 0.012
  8. DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Kr?ppel-Like Factor 4 Expression. Clin Cancer Res. 2017 Sep 15; 23(18):5585-5597.
    View in: PubMed
    Score: 0.011
  9. KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis. Cancer Cell. 2016 Mar 14; 29(3):324-338.
    View in: PubMed
    Score: 0.010
  10. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med. 2015 Sep; 4(9):1033-43.
    View in: PubMed
    Score: 0.010
  11. KLF4a up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology. 2010 Dec; 139(6):2135-45.
    View in: PubMed
    Score: 0.007
  12. Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 2008 Jun 15; 68(12):4631-9.
    View in: PubMed
    Score: 0.006
  13. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11.
    View in: PubMed
    Score: 0.006
  14. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis. 2006 Jan; 27(1):23-31.
    View in: PubMed
    Score: 0.005
  15. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005 Jun 01; 65(11):4809-16.
    View in: PubMed
    Score: 0.005
  16. Drastic down-regulation of Kr?ppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005 Apr 01; 65(7):2746-54.
    View in: PubMed
    Score: 0.005
  17. PBI-05204, a supercritical CO2 extract of Nerium oleander, suppresses glioblastoma stem cells by inhibiting GRP78 and inducing programmed necroptotic cell death. Neoplasia. 2024 08; 54:101008.
    View in: PubMed
    Score: 0.005
  18. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 2004 Mar 15; 64(6):2030-8.
    View in: PubMed
    Score: 0.005
  19. PPARd dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. 2023 11; 26(6):904-917.
    View in: PubMed
    Score: 0.004
  20. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003 Jan 23; 22(3):319-29.
    View in: PubMed
    Score: 0.004
  21. Experimental animal models of pancreatic carcinogenesis and metastasis. Int J Gastrointest Cancer. 2003; 33(1):43-60.
    View in: PubMed
    Score: 0.004
  22. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARd. Nat Commun. 2022 05 13; 13(1):2665.
    View in: PubMed
    Score: 0.004
  23. Suppression of Membranous LRP5 Recycling, Wnt/?-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P. Cell Rep. 2020 08 18; 32(7):108049.
    View in: PubMed
    Score: 0.004
  24. Methylation of HSP70 Orchestrates Its Binding to and Stabilization of BCL2 mRNA and Renders Pancreatic Cancer Cells Resistant to Therapeutics. Cancer Res. 2020 10 15; 80(20):4500-4513.
    View in: PubMed
    Score: 0.004
  25. Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019 03 01; 79(5):954-969.
    View in: PubMed
    Score: 0.003
  26. The Role of PPAR-d in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. Int J Mol Sci. 2018 Oct 26; 19(11).
    View in: PubMed
    Score: 0.003
  27. Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419.
    View in: PubMed
    Score: 0.003
  28. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):687-696.
    View in: PubMed
    Score: 0.003
  29. KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis. Cancer Res. 2016 04 15; 76(8):2419-31.
    View in: PubMed
    Score: 0.003
  30. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. Oncotarget. 2016 Feb 02; 7(5):5664-76.
    View in: PubMed
    Score: 0.003
  31. Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/?-Catenin Signaling. Cancer Res. 2015 Nov 15; 75(22):4778-4789.
    View in: PubMed
    Score: 0.003
  32. Kr?ppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. Clin Cancer Res. 2016 Jan 15; 22(2):502-12.
    View in: PubMed
    Score: 0.003
  33. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Clin Cancer Res. 2015 Feb 15; 21(4):844-53.
    View in: PubMed
    Score: 0.002
  34. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res. 2014 Aug 15; 20(16):4370-80.
    View in: PubMed
    Score: 0.002
  35. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and ?-catenin signaling in pancreatic ductal adenocarcinoma cells. Gastroenterology. 2014 Aug; 147(2):485-97.e18.
    View in: PubMed
    Score: 0.002
  36. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014 May 15; 20(10):2595-606.
    View in: PubMed
    Score: 0.002
  37. Dysregulated Kr?ppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology. 2012 Sep; 143(3):799-810.e2.
    View in: PubMed
    Score: 0.002
  38. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012 Feb 01; 72(3):655-65.
    View in: PubMed
    Score: 0.002
  39. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors of the antrum in mice. Gastroenterology. 2012 Mar; 142(3):531-42.
    View in: PubMed
    Score: 0.002
  40. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res. 2011 Aug 01; 71(15):5182-93.
    View in: PubMed
    Score: 0.002
  41. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010 Feb 01; 70(3):1111-9.
    View in: PubMed
    Score: 0.002
  42. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009 Apr 15; 69(8):3501-9.
    View in: PubMed
    Score: 0.002
  43. Inhibition of the growth and metastasis of human colon cancer by restoration of RUNX3 expression in cancer cells. Int J Oncol. 2008 Nov; 33(5):979-84.
    View in: PubMed
    Score: 0.002
  44. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol. 2008 Jul; 33(1):161-7.
    View in: PubMed
    Score: 0.002
  45. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer. 2007 Dec 15; 110(12):2682-90.
    View in: PubMed
    Score: 0.001
  46. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007 May 15; 67(10):4878-85.
    View in: PubMed
    Score: 0.001
  47. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006; 23(7-8):401-10.
    View in: PubMed
    Score: 0.001
  48. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res. 2006 Nov 01; 12(21):6386-94.
    View in: PubMed
    Score: 0.001
  49. Loss of Kr?ppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res. 2006 Nov 01; 12(21):6395-402.
    View in: PubMed
    Score: 0.001
  50. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev. 2006 Jun; 17(3):147-56.
    View in: PubMed
    Score: 0.001
  51. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5778-83.
    View in: PubMed
    Score: 0.001
  52. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8758-63.
    View in: PubMed
    Score: 0.001
  53. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93.
    View in: PubMed
    Score: 0.001
  54. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28.
    View in: PubMed
    Score: 0.001
  55. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis. 2005; 22(3):205-13.
    View in: PubMed
    Score: 0.001
  56. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004 Oct; 15(5):297-324.
    View in: PubMed
    Score: 0.001
  57. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17.
    View in: PubMed
    Score: 0.001
  58. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64.
    View in: PubMed
    Score: 0.001
  59. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80.
    View in: PubMed
    Score: 0.001
  60. Genome-wide search for loss of heterozygosity in Chinese patients with sporadic colorectal cancer. Int J Gastrointest Cancer. 2003; 34(1):39-48.
    View in: PubMed
    Score: 0.001
  61. [Combined gene therapy for murine liver cancer with interleukin-18 and cytosine deaminase genes]. Zhonghua Gan Zang Bing Za Zhi. 2001 Oct; 9(5):300-2.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.